Home LiteratureArticle Details
PMID: 20220001 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't

Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation.

Ortega Z, Díaz-Hernández M, Maynard CJ, Hernández F, Dantuma NP, Lucas JJ

Abstract

The presence of intracellular ubiquitylated inclusions in neurodegenerative disorders and the role of the ubiquitin/proteasome system (UPS) in degrading abnormal hazardous proteins have given rise to the hypothesis that UPS-impairment underlies neurodegenerative processes. However, this remains controversial for polyglutamine disorders such as Huntington disease (HD). Whereas studies in cellular models have provided evidence in favor of UPS-impairment attributable to expression of the N-terminal fragment of mutant huntingtin (N-mutHtt), similar studies on mouse models failed to do so. Furthermore, we have recently shown that the increase in polyubiquitin conjugates reported in the brain of N-mutHtt mice occurs in the absence of a general UPS-impairment. In the present study we aim to clarify the potential of N-mutHtt to impair UPS function in vivo as well as the mechanisms by which neurons may adapt after prolonged exposure to N-mutHtt in genetic models. By combining UPS reporter mice with an inducible mouse model of HD, we demonstrate for the first time polyglutamine-induced global UPS-impairment in vivo. UPS-impairment occurred transiently after acute N-mutHtt expression and restoration correlated with appearance of inclusion bodies (IBs). Consistently, UPS recovery did not take place when IB formation was prevented through administration of N-mutHtt aggregation-inhibitors in both cellular and animal models. Finally, no UPS-impairment was detected in old mice constitutively expressing N-mutHtt despite the age-associated decrease in brain proteasome activity. Therefore, our data reconcile previous contradictory reports by showing that N-mutHtt can indeed impair UPS function in vivo and that N-mutHtt aggregation leads to long lasting restoration of UPS function.

MeSH Terms
Animals Cell Aggregation/genetics Disease Models, Animal Gene Expression Regulation Humans Huntington Disease/genetics,metabolism Inclusion Bodies/genetics,metabolism Male Mice Mice, Transgenic Peptides/genetics,metabolism,physiology Proteasome Endopeptidase Complex/genetics,metabolism Proteasome Inhibitors Time Factors Ubiquitin/antagonists & inhibitors,genetics,metabolism
Chemicals
Peptides Proteasome Inhibitors Ubiquitin polyglutamine Proteasome Endopeptidase Complex
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Ortega Zaira
Centro de Biologia Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autonoma de Madrid and CiberNed, Madrid, Spain.
Díaz-Hernández Miguel
Maynard Christa J
Hernández Félix
Dantuma Nico P
Lucas José J
References (53)
53 references, click to expand
  1. Detection of polyglutamine aggregation in mouse models.
    Methods Enzymol. 1999;309:687-701 PMID: 10507055
  2. Possible involvement of proteasome inhibition in aging: implications for oxidative stress.
    Mech Ageing Dev. 2000 Jan 24;113(1):61-70 PMID: 10708250
  3. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease.
    Cell. 2000 Mar 31;101(1):57-66 PMID: 10778856
  4. Decreased levels of proteasome activity and proteasome expression in aging spinal cord.
    Neuroscience. 2000;98(1):149-56 PMID: 10858621
  5. Aggresomes, inclusion bodies and protein aggregation.
    Trends Cell Biol. 2000 Dec;10(12):524-30 PMID: 11121744
  6. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases.
    Neuron. 2001 Jan;29(1):15-32 PMID: 11182078
  7. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.
    Hum Mol Genet. 2001 May 1;10(10):1049-59 PMID: 11331615
  8. Impairment of the ubiquitin-proteasome system by protein aggregation.
    Science. 2001 May 25;292(5521):1552-5 PMID: 11375494
  9. The axial channel of the proteasome core particle is gated by the Rpt2 ATPase and controls both substrate entry and product release.
    Mol Cell. 2001 Jun;7(6):1143-52 PMID: 11430818
  10. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease.
    J Neurosci. 2001 Nov 15;21(22):8772-81 PMID: 11698589
  11. Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment.
    Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):727-32 PMID: 11792857
  12. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction.
    Physiol Rev. 2002 Apr;82(2):373-428 PMID: 11917093
  13. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay.
    Proc Natl Acad Sci U S A. 2002 Dec 10;99 Suppl 4:16400-6 PMID: 12200548
  14. A transgenic mouse model of the ubiquitin/proteasome system.
    Nat Biotechnol. 2003 Aug;21(8):897-902 PMID: 12872133
  15. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg.
    Neuron. 2003 Oct 9;40(2):427-46 PMID: 14556719
  16. Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity.
    J Cell Biol. 2003 Oct 13;163(1):109-18 PMID: 14557250
  17. Neuronal induction of the immunoproteasome in Huntington's disease.
    J Neurosci. 2003 Dec 17;23(37):11653-61 PMID: 14684867
  18. Testing the ubiquitin-proteasome hypothesis of neurodegeneration in vivo.
    Trends Neurosci. 2004 Feb;27(2):66-9 PMID: 15106649
  19. Molecular pathways to neurodegeneration.
    Nat Med. 2004 Jul;10 Suppl:S2-9 PMID: 15272266
  20. Protein aggregation and neurodegenerative disease.
    Nat Med. 2004 Jul;10 Suppl:S10-7 PMID: 15272267
  21. Generalized brain and skin proteasome inhibition in Huntington's disease.
    Ann Neurol. 2004 Sep;56(3):319-28 PMID: 15349858
  22. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death.
    Nature. 2004 Oct 14;431(7010):805-10 PMID: 15483602
  23. Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain.
    J Neurosci. 2004 Oct 20;24(42):9361-71 PMID: 15496672
  24. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation.
    Hum Mol Genet. 2005 Mar 1;14(5):679-91 PMID: 15661755
  25. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation.
    Mol Cell. 2005 Feb 4;17(3):351-65 PMID: 15694337
  26. Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease.
    Neurobiol Dis. 2006 Jan;21(1):228-36 PMID: 16111888
  27. Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease.
    J Neurosci. 2005 Oct 19;25(42):9773-81 PMID: 16237181
  28. Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target.
    Hum Mol Genet. 2006 Jan 1;15(1):33-44 PMID: 16311253
  29. Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain.
    J Neurochem. 2006 Sep;98(5):1585-96 PMID: 16787406
  30. Trinucleotide repeat disorders.
    Annu Rev Neurosci. 2007;30:575-621 PMID: 17417937
  31. Disease-associated prion protein oligomers inhibit the 26S proteasome.
    Mol Cell. 2007 Apr 27;26(2):175-88 PMID: 17466621
  32. Is the ubiquitin-proteasome system impaired in Huntington's disease?
    Cell Mol Life Sci. 2007 Sep;64(17):2245-57 PMID: 17604996
  33. Global changes to the ubiquitin system in Huntington's disease.
    Nature. 2007 Aug 9;448(7154):704-8 PMID: 17687326
  34. Docking of the proteasomal ATPases' carboxyl termini in the 20S proteasome's alpha ring opens the gate for substrate entry.
    Mol Cell. 2007 Sep 7;27(5):731-44 PMID: 17803938
  35. The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias.
    BMC Biochem. 2007 Nov 22;8 Suppl 1:S2 PMID: 18047739
  36. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice.
    J Cell Biol. 2008 Mar 24;180(6):1177-89 PMID: 18362179
  37. A common motif targets huntingtin and the androgen receptor to the proteasome.
    J Biol Chem. 2008 Aug 29;283(35):23950-5 PMID: 18586675
  38. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.
    Hum Mol Genet. 2008 Oct 15;17(20):3144-53 PMID: 18640989
  39. Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis.
    Hum Mol Genet. 2009 Jan 1;18(1):82-96 PMID: 18826962
  40. Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity.
    Genes Dev. 2008 Dec 1;22(23):3308-19 PMID: 19015277
  41. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse.
    Hum Mol Genet. 2009 Mar 1;18(5):898-910 PMID: 19066230
  42. Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in huntington disease.
    J Biol Chem. 2009 Feb 13;284(7):4398-403 PMID: 19074152
  43. The ubiquitin-proteasome reporter GFPu does not accumulate in neurons of the R6/2 transgenic mouse model of Huntington's disease.
    PLoS One. 2009;4(4):e5128 PMID: 19352500
  44. A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease.
    Biochim Biophys Acta. 2009 Jul;1792(7):664-75 PMID: 19419700
  45. Accumulation of ubiquitin conjugates in a polyglutamine disease model occurs without global ubiquitin/proteasome system impairment.
    Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13986-91 PMID: 19666572
  46. Cytomegalovirus promoter up-regulation is the major cause of increased protein levels of unstable reporter proteins after treatment of living cells with proteasome inhibitors.
    J Biol Chem. 2009 Oct 9;284(41):28253-62 PMID: 19679666
  47. Development of inhibitory synapses among striatal neurons in vitro.
    J Neurosci. 1989 Nov;9(11):3955-65 PMID: 2585061
  48. Primary culture of identified neurons from the visual cortex of postnatal rats.
    J Neurosci. 1986 Oct;6(10):3044-60 PMID: 3760948
  49. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.
    Cell. 1996 Nov 1;87(3):493-506 PMID: 8898202
  50. Control of memory formation through regulated expression of a CaMKII transgene.
    Science. 1996 Dec 6;274(5293):1678-83 PMID: 8939850
  51. Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?
    Neuron. 1997 Dec;19(6):1147-50 PMID: 9427237
  52. The ubiquitin system.
    Annu Rev Biochem. 1998;67:425-79 PMID: 9759494
  53. Aggresomes: a cellular response to misfolded proteins.
    J Cell Biol. 1998 Dec 28;143(7):1883-98 PMID: 9864362
Article Info
Journal
The Journal of neuroscience : the official journal of the Society for Neuroscience
Abbr.
J Neurosci
ISSN
1529-2401
Published
2010-03-10
Pages
3675-88
Language
English
Region
United States
NLM ID
8102140
PMCID
PMC6632247
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com